Company: LCTX
Filing Date: 2025-08-15
Form Type: S-8
Source: 0000950170-25-109396
Chunk: 0

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-08-15
Form: S-8
Chunk 0
---
<div align='center'>As filed with the Securities and Exchange Commission on August 15, 2025</div>

Registration No. 333-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Lineage Cell Therapeutics, Inc. (Exact name of Registrant as specified in its charter)

| California(State or other jurisdiction ofincorporation or organization)           |     | 94-3127919(I.R.S. employeridentification number) |
| 2173 Salk Avenue, Suite 200, Carlsbad, CA(Address of principal executive offices) |     | 92008(Zip Code)                                  |

Lineage Cell Therapeutics, Inc. 2021 Equity Incentive Plan (Full title of the plan) George A. Samuel III General Counsel and Secretary Lineage Cell Therapeutics, Inc. 2173 Salk Avenue, Suite 200 Carlsbad, CA 92008 (Name and address of agent for service) (442) 287-8990 (Telephone number, including area code, of agent for service) Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

| Large accelerated filer | ☐ | Accelerated filer         | ☐ |
| Non-accelerated filer   | ☒ | Smaller reporting company | ☒ |
|                         |   | Emerging growth company   | ☐ |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

<div align='center'>EXPLANATORY NOTE</div>

Lineage Cell Therapeutics, Inc. (“Lineage”), is filing this Registration Statement on Form S-8 with the U.S. Securities and Exchange Commission (the “Commission”) to register an additional 19,500,000 common shares of Lineage for issuance under the Lineage 2021 Equity Incentive Plan (the “2021